CD44 and glioma: For example, in 2001, it was demonstrated that high-grade gliomas expressed higher levels of RHAMM and CD44 than low-grade lesions and that RHAMM inhibition hindered proliferation and migration of glioma cells, both in the presence and in the absence of HA-based ECM (115).